InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.00%
)
Bitcoin
66,622.00
(
0.65%
)
Post# of 252205
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

apljack

Send PM Follow Ignore
Followers 6
Posts 703
Boards Moderated 0
Alias Born 09/23/2006

apljack

Re: pastemp post# 219635

Sunday, 06/17/2018 7:07:14 PM

Sunday, June 17, 2018 7:07:14 PM

Post# of 252205
PRTK- Sarecycline looks like a NDA approval candidate shoo-in and Omadacycline a strong candidate. Allergan at the ready for marketing of Sarecycline (Acne Vulgaris market is fairly extensive) and my cursory read of the balance sheet looks pretty good. Market cap is low. All in all, I wish I had found this earlier, my money's been on TTPH in this space. Why this stock has slid down is puzzling. Did they dilute? The only other thing I caught was their website had the NDA for Omadacycline being submitted Q1, '18. Doesn't appear that they've met that deadline.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up